^
    Back
    Association details:
    Biomarker:14-gene IGG signature
    Cancer:Solid Tumor
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    2239P - Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types

    Published date:
    10/16/2023
    Excerpt:
    The B-cell/IGG signature is a GE pattern strongly associated with TLS across cancer types, even independently of TILs. This signature could serve as a valuable tool for precisely measuring TLS and predicting clinical outcomes and response to immunotherapy in cancer patients.
    Trial ID:
    ACROPOLI